MCL: first-line VR-CAP delivers deep, durable response vs R-CHOP

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Patients with newly diagnosed mantle cell lymphoma (MCL) achieved deeper, more durable responses with first-line VR-CAP (bortezomib [Revlimid], rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) vs R-CHOP (rituximab [Rituxan] plus cyclophosphamide, vincristine, doxo...